|
 
- 积分
- 429
- 威望
- 429
- 包包
- 1768
|
本帖最后由 qianqianlaile 于 2011-3-21 11:29 编辑
l# v$ [ ]! O0 E" r8 S7 {
; h& ? k$ T5 F/ q# G' x% w* [INTRODUCTION
9 y1 ?# V2 j3 l: W1 a) \" ]- DCell therapy has tremendous potential in regenerative medicine, yet, there are concerns in / @4 {, Z( ^. u
the utility of cell therapy due to questions regarding different cell harvest and cultivation
0 T% [! Y" `. @: jmethods (Haack-Sorensen et al., 2008; Mannello and Tonti, 2007). Bone marrow derived
6 B/ B& ], \! {4 \3 kstem cells have been identified for a number of years, and there are a number of / {) G6 |/ E1 e) F! P+ u& |+ z9 @
ongoing clinical trials exploring the safety and efficacy of their use for a number of & u# E1 L2 M7 _* D* t m
clinical applications (Battiwalla and Hematti, 2009; Sadan et al., 2009; Satija et al.,
5 W' m0 j4 ]! \& Z9 V2009). There has been an increased interest in recent years in the potential of oral-1 w3 x; e. x- q/ {! \4 p
derived stem cells for cell therapy, primarily because they can be derived from a readily % S. u: K) r8 Z8 I; V) n
available source, extracted teeth (Gronthos et al., 2000; Miura et al., 2003; Seo et al.,
" G, `, W% B/ L ^, I) {2 B& @2004). These cells exhibit multipotency and regenerative capacities characteristic of
/ o l: `& ]6 l0 Q$ c5 e/ E+ z7 smesenchymal stem cells (Batouli et al., 2003; Shi et al., 2005) and have the capacity to
2 O- ~; u& W6 U3 nrepair and regenerate tooth structures in vivo (Krebsbach and Robey, 2002; Mao et al., 2006). + e3 i8 H: U* q7 f2 t
Because oral-derived stem cells have been more recently identified, clinical
/ ~; @7 Z- a- N( L! w- vprotocols are still being developed for their use. Regardless of the specific protocol
# Q# D, _2 b% C4 {( \% J c0 Oused, most current cell therapy approaches rely upon ex vivo cell expansion in order to , r" o5 d8 s1 j, h/ Z; \/ X
produce sufficient cell numbers for transplantation. Though a wide variety of protocols - [0 [1 v; b7 n0 n i% {! f# {
and culturing methods exist, one common aspect to most of them is the inclusion of
/ d# C9 O" b' Uanimal sera for cell expansion, in that it contains a rich source of nutrients and growth
6 @2 s& ]( [- Wfactors (Mannello and Tonti, 2007). Despite the widespread standard use of animal
" t) l! E% N, Q1 asera for in vitro cell culture (Freshney, 2000), there are several problems which exist 4 L$ [+ k5 Y* E* w0 L r. v8 o
relative to its use for clinical application.
B, O4 ^1 `, y4 V& v' |One of the central issues regarding limitations in using animal sera for clinical cell
" F$ I8 B3 ]( A* Utherapy protocols is that its components are highly variable and, in many cases,
5 x3 t! Q. R) s7 k$ `& kunknown. Though components of sera have identified, it has also been demonstrated
0 L: H$ b- M" p; i9 n9 i% R* Kthat consistency between different lots cannot be assured (Price and Gregory, 1982). In ! A4 I% b+ v# ]( D l7 N
the context of multipotent stem cells, serum components and concentrations have
5 e* F! u/ U7 f8 s) ^significant impact on cell survival and proliferative capacity, phenotype, and multipotent & U! v1 Z; O2 ^0 Y9 [" M, M
potential (Agata et al., 2009; Sotiropoulou et al., 2006). Additionally, for clinical use, the 2 N- ^/ L# t! \) t; c; D8 B
inclusion of xenogeneic serum for cell expansion carries immunological risks associated
% S$ u& V& q& r* B qwith the immunogenicity of serum proteins and the potential of transmission of prion 7 T- w- |0 x2 Y3 t) E; l
diseases and zoonoses (Shahdadfar et al., 2005). These concerns have led to efforts & F x+ G4 d, r* f! K- q3 d
aimed at incorporating FBS alternatives in cell expansion protocols, including the use of 6 r' K3 ~- m( X3 V. k- i& s( n9 u
autologous and allogeneic sera, and the proprietary manufacturing of serum-free media 3 k, U1 @7 o6 F/ W: r
formulations by different companies (Nakamura et al., 2008). Even with these approaches,7 S0 o, u! e& h7 z
there are limitations in the availability of both autologous and allogeneic
0 `0 N- L: v( u q! |, Jsera and companies do not freely disclose their proprietary “serum-free” media
# h0 h/ a, c3 ?* [2 i- qcomponents. These factors not only prohibit clinical translation, but also limit
* t( a |. R) K; b: ?# T& ywidespread use and study of more basic fundamental questions regarding specific ' i) E+ v) m4 m
mechanisms involved in the modulation of these media on cell function. As such, there - t& t( \1 m' o6 Q2 l) X( [" _
exists a need for the development of chemically-defined media which can propagate the
4 P' @" p8 N2 ~5 E0 ~cultivation of stem cells without adversely affecting cell function and phenotype / s* x+ F# p1 c' N; A* a
(Mannello and Tonti, 2007).
: F- {7 s2 s N# S* ]In this study, we aimed to develop a serum-free media (K-M) for the expansion o
/ L6 ~4 Q P3 H) p" J! r0 @dental-derived stem cells, including stem cells-derived from exfoliated deciduous (baby)
6 w* o v* ^- Z% p5 E6 Y# \4 gteeth (SHEDs) and periodontal ligament stems cells (PDLSCs). Cell expansion in this
& H0 K* S* ^# `. r* z( Imedia was compared to standard FBS containing media used to culture these cells,
# d1 E" C: E) o+ [2 A& ~7 a Sas well as three other serum-free media formulations (two of which are commercially available) # ^2 w* m7 I, u& ? \. ?% `
used for culture of mesenchymal stem cells. Additionally, through 9 K- l+ i: r V
differentiation assays and microarray analyses, multipotency and differential gene 4 j; w6 n! G, |. L9 O/ T6 g/ O: R
expression of 84 stem cell associated genes was examined between cells cultured in K-
4 ]0 x5 g5 g% n) CM vs. those cultured in FBS- containing media. |
|
发表于 2011-3-20 08:21
，脑子里也没有独家生产这个概念
，所以没理解。% X/ s7 u0 t& h% Y+ G